SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration


Get unlimited access to all IAM content